Published in Br J Hosp Med on November 01, 1990
Can you screen for ovarian cancer? J Natl Med Assoc (1995) 0.75
The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods (1998) 2.78
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet (1998) 1.79
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer (2001) 1.63
Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev (2001) 1.55
Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature (1998) 1.41
Phenytoin in pre-eclampsia. Lancet (1989) 1.40
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A (1997) 1.27
Predominant transgene expression in exocrine pancreas directed by the CMV promoter. DNA Cell Biol (2000) 1.25
Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol (2002) 1.21
Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet (2001) 1.21
Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG (2007) 1.15
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer (1999) 1.13
The role of CA 125 in screening for ovarian cancer. Int J Biol Markers (1999) 1.12
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Ascites and a raised serum Ca 125--confusing combination. J R Soc Med (2001) 1.08
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer (2002) 1.08
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG (2000) 1.03
Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol (2000) 1.02
A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci U S A (2000) 1.02
The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol (2005) 1.02
Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif (2009) 1.02
Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology (1999) 1.00
Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol (2001) 0.99
CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol (2000) 0.97
Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res (2000) 0.97
Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer (2007) 0.97
Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction. Int Immunol (2000) 0.97
Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG (2006) 0.96
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res (2000) 0.95
Screening for ovarian cancer. Ann Acad Med Singapore (1998) 0.93
Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol (2003) 0.90
Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol (2005) 0.90
Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol (2001) 0.89
Inhibitory effect of lipopolysaccharide on immune response after DNA immunization is route dependent. DNA Cell Biol (1998) 0.88
Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer (2001) 0.88
Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice. Transplantation (2000) 0.86
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol (1999) 0.85
Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.84
Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer (2009) 0.84
Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer (1999) 0.83
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest (2001) 0.83
Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol (2006) 0.81
Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts. Transplantation (2000) 0.81
Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst (1998) 0.81
Nucleic acid vaccines: tasks and tactics. Immunol Res (2001) 0.80
Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing. J Immunol (2001) 0.80
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol (2002) 0.79
Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology (2007) 0.79
Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody. Cell Transplant (2001) 0.79
Increased mortality in postmenopausal women with serum CA125 elevation. Gynecol Oncol (1999) 0.78
Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol (1999) 0.78
Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen. Transplantation (1996) 0.78
High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). Int J Cancer (2001) 0.78
Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG (2000) 0.78
Dietary protein restriction in artificially reared neonatal rats causes a reduction of insulin-like growth factor-I gene expression. Endocrinology (1989) 0.77
Transverse posterior cervicoisthmic rupture after gemeprost pessaries for termination. BMJ (1992) 0.77
p53 codon 72 polymorphism in vulval cancer and vulval intraepithelial neoplasia. Br J Cancer (2000) 0.77
Local production of anti-CD4 antibody by transgenic allogeneic grafts affords partial protection. Transplantation (2000) 0.77
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer (1995) 0.76
Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer. Gynecol Oncol (2004) 0.76
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. Int J Gynecol Cancer (2004) 0.76
Transgenic anti-CD4 monoclonal antibody secretion by mouse segmental pancreas allografts promotes long term survival. Transpl Immunol (2000) 0.76
No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis. Gynecol Oncol (1998) 0.76
Overcoming the poor immunogenicity of a protein by DNA immunization as a fusion construct. Immunol Cell Biol (2001) 0.76
Familial ovarian screening--effective or ineffective? Br J Cancer (2006) 0.76
A review of post-trachelectomy isthmic and vaginal smear cytology. Cytopathology (2004) 0.76
Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer (2000) 0.76
Comment on Elit et al.: prophylactic oophorectomy in Ontario. Fam Cancer (2001) 0.75
Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. Br J Cancer (2003) 0.75
Local secretion of a chimeric anti-CD4 antibody protects against graft rejection in the NOD mouse. Transplantation (2000) 0.75
A biochemical test for the direct assessment of endometrial function: measurement of the major secretory endometrial protein PP14 in serum during menstruation in relation to ovulation and luteal function. Hum Reprod (1990) 0.75
Genetic modification of an islet tumor cell line inhibits its rejection. Transplant Proc (1997) 0.75
Shutdown of immunological priming and presentation after in vivo administration of adenovirus. Gene Ther (2011) 0.75
Identifying the faces in the mirror: untangling transference and countertransference in self psychology. J Clin Psychol (2001) 0.75
Assessment of the depth of myometrial invasion in stage I endometrioid endometrial cancer using pancytokeratin immunohistochemistry. Int J Gynecol Cancer (2004) 0.75
Delayed rejection of fetal pig pancreas in CD4 cell deficient mice was correlated with residual helper activity. Xenotransplantation (2000) 0.75
Familial ovarian cancer. Methods Mol Med (2001) 0.75
A report on 169 saphenous aorto coronary bypasses. Med Times (1971) 0.75
OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem (1999) 0.75
Tumor markers in screening for ovarian cancer. Methods Mol Med (2001) 0.75
Analysis of acrolein in aged aqueous media. Comparison of various analytical methods with bioassays. J Agric Food Chem (1979) 0.75
Laparoscopic extraperitoneal paraaortic lymphadenectomy: a study of its applications in gynecological malignancies. Gynecol Oncol (2004) 0.75